Carcinoma

Voiceitt puts its AI to work, making the remote workplace inclusive

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Employment, Disability, Organization, Communication, Unemployment, Partnership, Intellectual, United, Education, Research, United Nations, Thrive, AI, Life, Statistics, Carcinoma, Disability studies, ChatGPT, Yann, Workplace, Vocal cords, TEL, WFH, Government, Cisco Webex, Human, Person, Nursing

TEL AVIV, Israel and STAMFORD, Conn. , April 1, 2024 /PRNewswire/ -- Voiceitt, the Israel-based leader in speech recognition technology for non-standard speech, announces its collaboration with Virtualahan, a leading organization in the Philippines that recruits and trains individuals with disabilities for meaningful employment opportunities. Together, the two organizations leverage cutting-edge AI-driven technologies to give people with disabilities a voice and facilitate opportunities for employment.

Key Points: 
  • With Voiceitt, people with disabilities can get a job, keep a job, and enjoy greater productivity and satisfaction on the job.
  • Voiceitt and Virtualahan are committed to changing these statistics by creating inclusive workplaces where individuals with disabilities can contribute their unique talents and skills.
  • "Our tech expands employment opportunities and can improve workplace productivity," said Alyson Pace, CEO of Voiceitt.
  • Voiceitt partners with organizations such as the Department of Intellectual and Developmental Disabilities in Tennessee to evaluate how technologies like Voiceitt can advance critical employment opportunities.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Wednesday, March 27, 2024
Gene, Mining, PPT, Cell, RMB, Patient, Rehabilitation, TCFD, Marketing, World Health Organization, HSI, Artesunate, Carcinoma, MSCI, FTG, Telehealth, Lithium, National Medical Products Administration, HKEX, Sustainability, SCLC, AA, KOD, NMPA, Growth, Hope, Fosun Pharma, S&P, Task force, Club Med, Dragon

HONG KONG, March 27, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2023 (the "Reporting Period").

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Thanks to the Group's global business presence and continuous innovation, industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing  a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

Retrieved on: 
Monday, March 11, 2024
HER2, Cervical cancer, Congress, ECOG, Immunotherapy, Progression-free survival, DCR, Patient, Research, IIB, Șaeș, Safety, Dor, Carcinoma, ESGO, Adenocarcinoma, PFS, FIGO, ADC, Independent Review Committee, Pharmaceutical industry

The cervical cancer cohort includes patients with recurrent or metastatic cervical cancer who have progressed on at least 1L anti-tumor therapy and have HER2 IHC ≥1+.

Key Points: 
  • The cervical cancer cohort includes patients with recurrent or metastatic cervical cancer who have progressed on at least 1L anti-tumor therapy and have HER2 IHC ≥1+.
  • As of October 31, 2023, 25 patients with cervical cancer were enrolled with a median age of 56 years (range: 35-66).
  • In conclusion, RC48 demonstrates a manageable safety profile and positive efficacy in HER2-expressing r/m cervical cancer patients, suggesting it to be a promising new treatment for HER2-expressed cervical cancer.
  • I am delighted to share an oral presentation on the evaluation of our proprietary ADC Disitamab Vedotin at ESGO 2024.

Zenith Epigenetics Proudly Supports Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Head, NUT, Aggression, Neck, Quality of life, Health, Zenith, Cell, Prevalence, Prognosis, Patient, Nervous tissue, Clinical trial, NUT carcinoma, Disease, Survival, Sympathetic nervous system, Diagnosis, Metastasis, BET, Carcinoma, Cancer, Pharmaceutical industry

ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
  • Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
  • This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
  • We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024
Mohs surgery, Cancer, Carcinoma, SRT, Research, Pathology, FDA, Ageing, Food, RCM, Dermatology, Bed, Physiology, Epidermis, Vision, AAD, NMSC, Skin cancer, PAI, Patent, Patient, Tanning, United, American Academy, Medical imaging

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Research, AbbVie, Sale, Carcinoma, Lung cancer, Webcast, Anal cancer, Acute myeloid leukemia, Trial of the century, Melanoma, Head, Neck, SCLC, SCCHN, GAAP, ADAM, B7, Therapy, NSCLC, Syndrome, CD123, ID, AACR, Conference, Safety, Enoblituzumab, ImmunoGen, Clinical trial, Half-life, IND, Conference call, Docetaxel, ASCO, Telephone, Cancer, Spacecraft, HEAT, ADAM9, ADC, Society, Patient, Pharmaceutical industry

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
Head, Restart, Neoplasm, Food, Government, Safety, Lawrence, Massachusetts, PMDA, Patient, Carcinoma, D&O, Brain, Lung cancer, Clinical trial, Alpha, G&A, Radiation, Pancreatic cancer, Liver disease, Pharmaceutical industry

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
Online, Carboplatin, CRDF, SAN, Cancer, Progression-free survival, PDX, Cetuximab, EGFR, Bev, Carcinoma, FOLFIRI, PLK1, AACR, Bevacizumab, RAS, Cisplatin, Ovarian cancer, Abstract, Paclitaxel, Patient, Clinical trial, Mutation, Publication, Vaccine

“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.

Key Points: 
  • “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
  • We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
  • The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.

Auron Announces Poster Presentations at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Neoplasm, AML, SCLC, AI, NEPC, Growth, Carcinoma, AACR, KAT2B, Doctor of Philosophy, Therapy, Machine learning, Acute myeloid leukemia, Research, Cancer, Mobile phone

Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.

Key Points: 
  • Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.
  • AURIGIN utilizes a single cell multi-omics atlas of human development and AI machine learning to identify the most relevant genetic targets in cancer cell plasticity.
  • Using AURIGIN to identify disrupted cell states, Auron is developing targeted treatments to revert cancer cells to a normal, quiescent state to stop tumor growth and proliferation.
  • At AACR, Auron will also present in vitro and in vivo data from its first-in-class, novel program targeting KAT2A/B, a histone acetyltransferase identified by AURIGIN that is associated with multiple tumor types.